FDA Panel Weighs Transformative Multi-Cancer Blood Test, Emphasizing Adherence to Existing Screenings
admin A pivotal discussion by an advisory panel to the U.S. Food and Drug Administration (FDA)...
Biotech, Pharma & Cancer Drug Development
Merck reveals study success, and possible safety worries, for eye drug hopeful
A significant medicine acquired by Merck & Co. in a $1.3 billion buyout, Remigromig, has...
Enveda Biosciences Secures $311 Million Series E, Accelerating AI-Driven Natural Product Pipeline into Advanced Clinical Stages
Colorado-based Enveda Biosciences, a rapidly ascending biotech firm leveraging artificial intelligence to explore the vast...
Enveda, an AI drugmaker, banks $311M in venture funding
Colorado-based emerging biotech firm Enveda Biosciences has announced the successful closure of a Series E...
Enveda Biosciences Secures $311 Million in Series E Funding to Accelerate AI-Driven Drug Pipeline for Immune Diseases and Obesity
Colorado-based Enveda Biosciences, a pioneering force in artificial intelligence-driven drug discovery, has successfully closed a...
Barzolvolimab Shows Unprecedented Efficacy in Chronic Hives but Raises Safety Questions with Anaphylaxis Cases
Celldex Therapeutics’ experimental drug, barzolvolimab, has presented a complex picture to the biopharmaceutical world, demonstrating...
Amgen reports a Phase 3 win with Sjögren’s drug candidate
Amgen Inc. has announced that dazodalibep, a investigational therapy for Sjögren’s syndrome, has successfully met...
Viking shares surge on updated obesity drug data
Cambridge, MA – September 22, 2026 – New data emerging from Viking Therapeutics’ Phase 2...
Trump Administration’s Most-Favored-Nation Drug Deals Threaten to Undercut Billions in Projected Medicare Savings
President Donald Trump’s "most-favored-nation" (MFN) agreements with pharmaceutical companies, purportedly designed to curb drug prices...
Compass Pathways’ COMP360 Poised to Transform Depression Treatment, Leveraging Spravato-Built Interventional Psychiatry Infrastructure
Seven years ago, the pharmaceutical landscape for depression underwent a significant shift when Johnson &...
